Abstract
Our understanding of the biology and clinical behavior of serous neoplasms of the ovary has changed enormously over the past decade. It is now clear that although all serous tumors share a cell type reflecting tubal epithelium in various levels of differentiation, they appear to have different origins and distinct behaviors. Benign and borderline serous neoplasms, the most common variety, arise through a progressive accumulation of molecular defects and appear to arise in the ovary, possibly from endometriosis. High-grade serous carcinomas, in contrast, seem to arise, at least in part, on the epithelium of the distal fallopian tube.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gurung A, Hung T, Morin J, Gilks CB. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013;62(1):59–70. Epub 2012/12/18.
Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol. 2012;126(2):279–85. Epub 2012/05/05.
Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64(19):6915–8. Epub 2004/10/07.
Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM, et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest. 2004;84(6):778–84. Epub 2004/04/13.
Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010;177(4):1611–7. Epub 2010/08/31.
Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226(3):413–20. Epub 2011/11/22.
Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2003;2(2):73–8. Epub 2003/10/24.
Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5(1):35–44. Epub 2007/04/26.
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–9. Epub 2007/01/27.
Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010;10(11):803–8. Epub 2010/10/15.
Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006;103(3):883–7. Epub 2006/06/30.
Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM, et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol. 2004;35(8):910–7. Epub 2004/08/07.
Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20(11):1319–30. Epub 1996/11/01.
Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol. 2002;26(9):1129–41. Epub 2002/09/10.
Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005;29(6):707–23. Epub 2005/05/18.
Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer. 2002;95(4):791–800. Epub 2002/09/05.
Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26(9):1111–28. Epub 2002/09/10.
Slomovitz BM, Caputo TA, Gretz 3rd HF, Economos K, Tortoriello DV, Schlosshauer PW, et al. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol. 2002;26(5):592–600. Epub 2002/04/30.
Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012;13(3):e103–15. Epub 2012/03/03.
McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol. 2010;22(5):462–72. Epub 2010/06/10.
Tavassoli FA, Devilee P, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003. 432 p.
Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005;18 Suppl 2:S33–50. Epub 2005/03/12.
Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31(5):539–57. Epub 2000/06/03.
Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol. 2011;123(3):511–6. Epub 2011/09/16.
Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001;25(4):419–32. Epub 2001/03/21.
Crum CP, Nucci MR, Lee KR. Diagnostic gynecologic and obstetric pathology. 2nd ed. Philadelphia: Saunders/Elsevier; 2011. xiv, 1202 p.
Silva EG, Tornos C, Zhuang Z, Merino MJ, Gershenson DM. Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol. 1998;17(1):1–6. Epub 1998/02/25.
Prade M, Spatz A, Bentley R, Duvillard P, Bognel C, Robboy SJ. Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions. Int J Gynecol Pathol. 1995;14(1):87–91. Epub 1995/01/01.
Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31(8):1168–74. Epub 2007/08/02.
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496–504. Epub 2004/04/17.
Yemelyanova A, Mao TL, Nakayama N, Shih IM, Kurman RJ. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol. 2008;32(12):1800–6. Epub 2008/09/10.
Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008;132(3):402–23. Epub 2008/03/06.
Blaustein A, Kurman RJ. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. xv, 1246 p.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Colón, E.C., Carlson, J.W. (2014). Serous Neoplasms of the Ovary. In: Wilkinson, N. (eds) Pathology of the Ovary, Fallopian Tube and Peritoneum. Essentials of Diagnostic Gynecological Pathology. Springer, London. https://doi.org/10.1007/978-1-4471-2942-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2942-4_9
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2941-7
Online ISBN: 978-1-4471-2942-4
eBook Packages: MedicineMedicine (R0)